Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Pacira BioSciences, Inc. (PCRX) had Revenue of $168.92M for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$168.92M
Net Income	$4.81M
Cost of Goods Sold	$34.31M
Gross Profit	$134.62M
Operating Expenses	$166.93M
Operating Income	$1.99M
Non-Operating Income/Expense	$6.72M
Pre-Tax Income	$8.71M
Normalized Pre-Tax Income	$8.71M
Income after Taxes	$4.81M
Income from Continuous Operations	$4.81M
Consolidated Net Income/Loss	$4.81M
Normalized Income after Taxes	$4.81M
EBIT	$1.99M
EBITDA	$24.02M
Weighted-Average Shares Outstanding (Basic)	46.27M
Weighted-Average Shares Outstanding (Diluted)	46.53M
Earnings per Share (EPS) (Basic)	$0.10
Earnings per Share (EPS) (Diluted)	$0.10
Balance Sheet Financials
Current Assets	$759.96M
Property, Plant, and Equipment	$164.45M
Long-Term Assets	$826.71M
Total Assets	$1.59B
Current Liabilities	$314.73M
Long-Term Debt	$381.29M
Long-Term Liabilities	$473.40M
Total Liabilities	$788.13M
Common Equity	$798.54M
Tangible Shareholders Equity	$342.05M
Shareholders Equity	$798.54M
Common Shares Outstanding	46.28M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$35.46M
Cash Flow from Investing Activities	$-25.63M
Cash Flow from Financial Activities	$-2.99M
Beginning Cash	$276.77M
End Cash	$283.61M
Increase/Decrease in Cash	$6.84M
Stock-Based Compensation	$14.55M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.41
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.32
Debt to Equity Ratio	0.73
Gross Margin	79.69%
Operating Margin	1.18%
EBIT Margin	1.18%
EBITDA Margin	--
Pre-Tax Profit Margin	5.15%
Profit Margin	2.85%
Free Cash Flow	$26.91M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.11
Inventory Turnover	0.26
Receiveable Turnover	1.61
Days Sales in Receivables	55.81
Return on Equity	0.60%
Return on Tangible Equity	1.41%
Return on Assets	0.30%
Return on Investments	0.41%
Book Value Per Share	$17.25
Free Cash Flow per Share	$0.58
Operating Cash Flow per Share	$0.76

Data from Zacks Investment Research, Inc.